Compare DexCom, Inc. (DXCM) vs FMC Corp (FMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs FMC Corp — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while FMC Corp trades at $8.35 (market cap $1.39B). The key difference: DexCom, Inc. is far larger — about 22.9× FMC Corp's market cap, and FMC Corp pays a 3.59% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and FMC Corp for 68 Days on average.
| DXCM | FMC | |
|---|---|---|
Market Cap | $31.86B | $1.39B |
Volume | 3,607,070 | 4,145,979 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $30.63 |
52-Week Low | $54.84 | $8.35 |
Typical Hold Time | 62 Days | 68 Days |
Enterprise Value | $31.32B | $5.19B |
Dividend Yield | — | 3.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
FMC trades at $8.92, down 1.87% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows weak profitability with a net income margin of -84.83% and negative ROE of -91.47% for 2025, though recent quarterly EPS beats offer some optimism. Analyst consensus is divided with a near-even split between Buy and Hold ratings, and a $14.60 price target suggests significant upside from current levels. Recent news highlights regulatory progress for rimisoxafen in Brazil and a minority equity investment from Tessenderlo Group.
The outlook for FMC hinges on successful deleveraging and product approvals, but high debt and cyclical industry pressures pose substantial risks. While valuation ratios like P/S of 0.34 appear attractive, persistent negative margins and volatile cash flows warrant caution. The stock presents a speculative opportunity for investors betting on a turnaround, but near-term headwinds in the agricultural sector may limit upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →
